IDEAYA Biosciences Inc at Goldman Sachs Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay. With that out of the way, welcome. Thanks so much. Maybe we can just start kind of high-level. I'd love to get a bit of an overview of IDEAYA, what you do, and a focus on the key value drivers over the next couple of months?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Maybe let's start with the most recent update because you did have data last week in an ASCO in the neoadjuvant uveal melanoma space. I mean, maybe let's just start with a brief refresher on what exactly you presented. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 10, 2024 / 12:00PM, IDYA.OQ - IDEAYA Biosciences Inc at Goldman Sachs Global Healthcare Conference

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Great. Maybe you could contextualize for us how, like, the 75% preservation of the eye -- how is that clinically meaningful or how does that compare?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Great. And we do expect another data set from the company-sponsored study that you referenced. Remind us the differences between those two studies and how we should think about what that trial will show.

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Yeah. And how do these data and the robustness of results inform your strategy as you think about neoadjuvant and adjuvant uveal melanoma on the forward? And what do you plan to request as you go into this Type C meeting with the FDA? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 10, 2024 / 12:00PM, IDYA.OQ - IDEAYA Biosciences Inc at Goldman Sachs Global Healthcare Conference

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay. This approach obviously would be a pretty, like, paradigm-changing treatment regimen in uveal melanoma. So I guess, what do you think you need to show to change behavior as you think about going to the physicians and convincing them to use this in neoadjuvant and adjuvant uveal melanoma?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Yeah, maybe before we talk about the metastatic setting for a bit, how are you thinking about the market opportunity here in neoadjuvant uveal melanoma and adjuvant as well?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay. And maybe we'll take that as a segue to the metastatic setting. So maybe first, just you're enrolling patients in a registrational trial, when are the next expected updates?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : And remind us what the prior study showed and what this study is powered to demonstrate with respect to PFS.

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay. And as you mentioned, there is a competitive agent in the space. So talk to us about how you think about the market opportunity in metastatic uveal melanoma. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 10, 2024 / 12:00PM, IDYA.OQ - IDEAYA Biosciences Inc at Goldman Sachs Global Healthcare Conference

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay. great. And are there any other indications where you see a role for daro or the combination? And maybe you can just expand on what those look like.

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay, great. Maybe we'll switch gears here and go to IDE397. Maybe first, it's a MAT2A inhibitor being developed in patients with MTAP deletion. Maybe if you could just briefly remind us of the mechanistic rationale for this molecule and how it differs from the PRMT5 inhibitors that are also in development here?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay, that's helpful. We did see a number of the monotherapy updates around the PRMT5 inhibitors last fall. I guess, how do you think about the differentiation potential of a combination approach?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Yeah. You did also report some that you'd hit RP2D for the monotherapy a couple of weeks ago at a high level, obviously. You didn't show the data, but what are you seeing in those monotherapy cohorts? And how does that kind of inform your expectations for the combination?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay. I think I've got a question on that later. But for now, I'm going to establish the Amgen combination. Just remind us the specifics of that collaboration and kind of where you are in that clinical study, when we can get next data.

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay. And maybe we'll go to it now. You've talked a little bit this year about some preclinical work around the MTAP space. What are you optimizing for relative to your existing, like, asset in the space as you think about bringing new candidates forward?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : No, your next asset.

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay. Maybe we'll switch gears again and go to IDE161 which is the PARG inhibitor. I guess for that program, maybe you can just refresh us on what you've shown in terms of clinical data to date.

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay. And in terms of -- I guess you've talked about this a little. But in some of your programs, you're really focused on the combination approaches. How do you think about this one as a monotherapy versus a combination? And in which indications would -- like, which of those two strategies makes the most sense?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay. In the past, you've put out some press releases in terms of the early results you're seeing, et cetera. But as we think about the next clinical updates that you want to share, how many patients should we be expecting, what kind of duration, how many doses. Just talk to us about those parameters. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 10, 2024 / 12:00PM, IDYA.OQ - IDEAYA Biosciences Inc at Goldman Sachs Global Healthcare Conference

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay. And there are some other assets that have sort of come into the space behind you all. I guess, how are you thinking about the competitive landscape as it's evolving with respect to the PARG inhibitors?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay. You're also working through some pre-IND work for a Werner Helicase program. This has obviously been a pretty tough target to crack. So what enabled you to generate the breakthrough in terms of getting a Werner Helicase program?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : I know there's some limitations around what you can share, but could you double-click a little bit on the competitive landscape? There's a couple of different features of the molecules that are up for debate. I think most obviously, the covalent versus non-covalent. How do you think about the parameters that are important as you're solving for this Werner Helicase structure? And could you just give us what you can in terms of that competitive landscape?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Sure. Okay. Maybe talking about your other partnership with GSK, you do have the Pol Theta program. So if you could just give us a quick update on that one. I know it's not been quite as much of a focus from the investor side. So where are we there?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay. We've kind of done a really quick runthrough, very large pipeline, but kind of underlying all of that is the drug discovery capabilities. So maybe you could just spend a minute talking about how you leverage AI and machine learning to further the drug development that you guys have all done. And where do these technologies kind of fit in your discovery process?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Okay. Any other assets in the pipeline or in early-stage development that we haven't talked about or that you want to make sure we get through before we wrap up here in a second?

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Really bearing the lead here. You're bearing the lead here (multiple speakers)

Question: Corinne Johnson - Goldman Sachs Co - Analyst : Perfect. I love breaking news. Okay. Maybe last question, because it's biotech. Cash runway. I know you have plenty, but just an update.